A Clinical Study to Evaluate the Efficacy and Satisfaction of the Skinceuticals Skin Care Product (CE) for Skin Repair Post Fraxel Laser Treatment
A Prospective, Single-Center, Single-Blind, Randomized Split-Face Controlled Clinical Study to Evaluate the Efficacy and Satisfaction of the Skinceuticals Skin Care Product (CE) for Skin Repair Post Fraxel Laser Treatment in Real World Clinical Practice
1 other identifier
interventional
50
0 countries
N/A
Brief Summary
A Prospective, Single-center, Single-blind, Randomized split-face, controlled trial will be conducted. The goal of this clinical trial is to evaluate the efficacy and satisfaction of the Skinceuticals skin care product (CE) for skin repair following fraxel laser treatment and explore the medical value of fraxel laser therapy combined with Skinceuticals skin care product
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2023
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 3, 2023
CompletedFirst Posted
Study publicly available on registry
April 14, 2023
CompletedStudy Start
First participant enrolled
April 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedApril 14, 2023
April 1, 2023
6 months
April 3, 2023
April 3, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Change in erythema score
Scoring criteria: 0 (no erythema), 1 (mild erythema), 2 (moderate erythema), and 3 (severe erythema)
at day 7 post-procedure
Secondary Outcomes (8)
Change from baseline in erythema score
days 1, 3, 5 post-procedure
Change from baseline in edema score
days 1, 3, 5 ,7 post-procedure
Change from baseline in Erythema Index (EI)
days 1, 3, 5 ,7 post-procedure
Change from baseline in melanin index(MI) Change from baseline in melanin index(MI)
days 1, 3, 5 ,7 post-procedure
Change from baseline in stratum corneum water content
days 1, 3, 5 ,7 post-procedure
- +3 more secondary outcomes
Study Arms (2)
Test group
EXPERIMENTALfraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
Control group
OTHERfraxel laser therapy combined with routine moisturizing and sun protection
Interventions
fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
fraxel laser therapy combined with routine moisturizing and sun protection
Eligibility Criteria
You may qualify if:
- Chinese subjects aged 18-65 years (inclusive);
- Subjects with Fitzpatrick skin type II-IV;
- Subjects with consistent facial skin status on both sides and planned to receive fraxel laser treatment;
- Subjects are willing to follow the requirements of the study protocol and complete the corresponding procedures;
- Subjects understand the nature of the study and sign the informed consent form (ICF).
You may not qualify if:
- Subjects with photosensitive skin or photosensitization-related diseases;
- Subjects with a history of skin pigmentation, such as pigmentation caused by sex hormone factors (pregnancy, oral contraceptives);
- Subjects with hypertrophic scar or scar constitution;
- Subjects with autoimmune diseases, endocrine diseases or liver diseases that may lead to skin color changes;
- Subjects who have received steroid/phototoxic drugs or laser treatment on the face within 3 months before enrollment;
- Subjects with a history of sun exposure within 2 weeks prior to enrollment;
- Subjects who are known to be contraindicated to fraxel laser therapy or CE (or allergic to other skin care components);
- Subjects with known infection and inflammation in the intended treatment site;
- Female subjects who are pregnant, lactating or plan to become pregnant;
- Subjects who plan to use other drugs affecting skin color or intend to undergo other laser therapy and sunbathing during the treatment;
- Subjects who are participating in other drug or medical device clinical trials;
- Other subjects who are not suitable for this study as assessed by the investigator
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 3, 2023
First Posted
April 14, 2023
Study Start
April 17, 2023
Primary Completion
September 30, 2023
Study Completion
December 31, 2023
Last Updated
April 14, 2023
Record last verified: 2023-04